TITLE

HEALTH CANADA ACCEPTS SANTHERA'S NDS FOR SNT-MC17

PUB. DATE
January 2008
SOURCE
Worldwide Biotech;Jan2008, Vol. 20 Issue 1, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of Santhera Pharmaceuticals' New Drug Submission application for SNT-MC17, used for the treatment of Friedreich's Ataxia (FRDA), by Health Canada. The drug has demonstrated its effectiveness in FRDA patients on neurological and cardiac endpoints in several studies.
ACCESSION #
28025762

 

Related Articles

  • Santhera Shares Plunge as Ataxia Trial Misses Goal. Hollingsworth, Catherine // BioWorld Today;5/20/2009, Vol. 20 Issue 96, p1 

    The article reports on the failure of Santhera Pharmaceuticals Holding AG's Phase III trial of Catena for Friedreich's ataxia. The trial failed to hit the mark partly because of the fact that patients on placebo improved unexpectedly. Negative outcome of the trials caused the company's shares to...

  • Canadian Approval but European Rebuff for Santhera's Idebenone. Sheridan, Cormac // BioWorld International;7/30/2008, Vol. 13 Issue 31, p1 

    The article presents an update on Santhera Pharmaceuticals AG. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) rejected an application for idebenone as a treatment for Friedreich's ataxia, despite a positive opinion released by Health Canada on...

  • Santhera's Idebenone Falls Short in Second Pivotal Trial. Sheridan, Cormac // BioWorld Today;5/21/2010, Vol. 21 Issue 98, p1 

    The article reports on the failure of the Phase III trial of idebenone from Santhera Pharmaceutical Holdings AG for the treatment of Friedreich's ataxia (FRDA), a progressive neuromuscular degenerative condition characterized by loss of muscle control and heart enlargement. Previously, the drug...

  • Good Data have Santhera Eying Approval Filings Next Year. Sheridan, Cormac // BioWorld Today;6/17/2010, Vol. 21 Issue 116, p4 

    The article reports that share price in Santhera Pharmaceuticals AG increased by nearly 11 percent to 7.95 U.S. dollars following its plans to gain approval for its idebenon drug called Catena to treat Leber's hereditary optical neuropathy (LHON). The drug was tested in the Rescue of Hereditary...

  • Health Canada drug approval process slower than in Europe and US.  // British Columbia Medical Journal;Jun2013, Vol. 55 Issue 5, p234 

    The article deals with a report the Fraser Institute which revealed that the drug approval process by Health Canada takes nearly a year which is slower than in Europe and the U.S.

  • Idebenone Falls Short in Second Pivotal Trial.  // Bioworld Week;5/24/2010, Vol. 18 Issue 21, p5 

    The article reports on the effect of the second Phase III trial failure of idebenone on Liestal, Switzerland-based Santhera Pharmaceutical Holdings AG's Friedreich's ataxia program.

  • Prostate Cancer: OS AND RPFS BENEFITS IN CHEMO-NAIVE MCRPC. So, Alan // Oncology Exchange;Aug2012, Vol. 11 Issue 3, p31 

    The article focuses on the results of the COU-AA-302 randomized trial which use abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). It says that AA has shown beneficial activity in patients with mCRPC as well as disease...

  • Clinical mistrial? (USA). Miller, Adam // CMAJ: Canadian Medical Association Journal;4/16/2013, Vol. 185 Issue 7, pE285 

    The article reports that Health Canada, the Canadian department of health, is creating awareness among consumers and health care professionals regarding the use of drug cinacalcet (sensipar) that is not approved to be prescribed to a patient under the age of 18.

  • Regulatory approval time for hormonal contraception in Canada, the United States and the United Kingdom, 2000-2015: a retrospective data analysis. Troskie, Christine; Soon, Judith A.; Albert, Arianne Y.; Norman, Wendy V. // CMAJ Open;Oct2016, Vol. 4 Issue 4, pE654 

    Background: Access to a wide range of contraceptive methods improves prevention of unintended pregnancy by ensuring the best method fit for each individual. We compared approval times of new hormonal contraceptives by Health Canada, the US Food and Drug Administration (FDA), and the UK Medicines...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics